Cargando…

The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab

Dismal prognosis of glioblastoma (GBM) prompts for the identification of response predictors and therapeutic resistance mechanisms of current therapies. The authors investigated the impact of c-Met, HGF, VEGFR2 expression and microvessel density (MVD) in GBM patients submitted to second-line chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carvalho, Bruno, Lopes, José Manuel, Silva, Roberto, Peixoto, Joana, Leitão, Dina, Soares, Paula, Fernandes, Ana Catarina, Linhares, Paulo, Vaz, Rui, Lima, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966794/ https://www.ncbi.nlm.nih.gov/pubmed/33727583 http://dx.doi.org/10.1038/s41598-021-85385-1

Ejemplares similares

Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy
por: Bastos, António G. P., et al.
Publicado: (2022)

High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma
por: Alves, Bárbara, et al.
Publicado: (2023)

Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance?
por: Linhares, Paulo, et al.
Publicado: (2020)

Glioblastoma in the elderly: Therapeutic dilemmas
por: Pereira, André F., et al.
Publicado: (2015)

Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation
por: Linhares, Paulo, et al.
Publicado: (2013)

VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
por: Michaelsen, Signe R, et al.
Publicado: (2018)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Using a Dual CRISPR/Cas9 Approach to Gain Insight into the Role of LRP1B in Glioblastoma
por: Peixoto, Joana, et al.
Publicado: (2023)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2
por: Navis, Anna C., et al.
Publicado: (2013)

Genetic variations in VEGF and VEGFR2 and glioblastoma outcome
por: Sjöström, S., et al.
Publicado: (2010)

Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo
por: Szabo, Emese, et al.
Publicado: (2016)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial
por: Morgan, Robert D., et al.
Publicado: (2022)

Integrated Metabolomics and Transcriptomics Analysis of Monolayer and Neurospheres from Established Glioblastoma Cell Lines
por: Peixoto, Joana, et al.
Publicado: (2021)

Role of bevacizumab therapy in the management of glioblastoma
por: Peak, Scott J, et al.
Publicado: (2010)

Bevacizumab for Glioblastoma—A Promising Drug or Not?
por: Nagane, Motoo, et al.
Publicado: (2013)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells
por: Miranda-Gonçalves, Vera, et al.
Publicado: (2017)

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
por: Chu, Jie Sheng, et al.
Publicado: (2013)

Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)
por: Zhang, Qian, et al.
Publicado: (2020)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

VEGFR-2 Expression in Glioblastoma Multiforme Depends on Inflammatory Tumor Microenvironment
por: Jaal, Jana, et al.
Publicado: (2015)

Analysis of a synchronous gliosarcoma and meningioma with long survival: A case report and review of the literature
por: Linhares, Paulo, et al.
Publicado: (2013)

Weichang’an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer—Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1
por: Pan, Chuan-Fang, et al.
Publicado: (2020)

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer
por: Chionh, Fiona, et al.
Publicado: (2022)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
por: Bertaut, Aurélie, et al.
Publicado: (2016)

Spinal Dissemination of Intracranial Glioblastoma in Bevacizumab Era: a Potential Bevacizumab-induced Mechanism
por: Kaloshi, Gentian, et al.
Publicado: (2014)

MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation
por: Chen, Tom T., et al.
Publicado: (2015)

Breast Cancer Molecular Subtypes Differentially Express Gluconeogenic Rate-Limiting Enzymes—Obesity as a Crucial Player
por: Luís, Carla, et al.
Publicado: (2023)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
por: Lee, Eudocia Q., et al.
Publicado: (2019)

Berberine inhibits angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway
por: Jin, Fa, et al.
Publicado: (2019)

Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma
por: PURCARU, S.O., et al.
Publicado: (2015)

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
por: Nagpal, Seema, et al.
Publicado: (2011)

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab
por: Wagle, Naveed, et al.
Publicado: (2010)

Histopathological investigation of glioblastomas resected under bevacizumab treatment
por: Tamura, Ryota, et al.
Publicado: (2016)

Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
por: Tamura, Ryota, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tmekmo05f7ek9ro089rd3d1d69